Jones K, Muehlmann AM, Musgrave M, Penrose CT. Short-term survivorship of Truliant® total knee arthroplasty implants utilizing the American Joint Replacement Registry. World J Orthop 2025; 16(7): 106281 [DOI: 10.5312/wjo.v16.i7.106281]
Corresponding Author of This Article
Amber M Muehlmann, PhD, Clinical Affairs, Exactech, Inc., 2320 NW 66th Court, Gainesville, FL 32653, United States. amber.muehlmann@exac.com
Research Domain of This Article
Orthopedics
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Orthop. Jul 18, 2025; 16(7): 106281 Published online Jul 18, 2025. doi: 10.5312/wjo.v16.i7.106281
Short-term survivorship of Truliant® total knee arthroplasty implants utilizing the American Joint Replacement Registry
Kirstin Jones, Amber M Muehlmann, Mark Musgrave, Colin T Penrose
Kirstin Jones, Amber M Muehlmann, Clinical Affairs, Exactech, Inc., Gainesville, FL 32653, United States
Mark Musgrave, Department of Orthopaedics, Crystal Clinic Orthopaedic Center, Fairlawn, OH 44333, United States
Colin T Penrose, Department of Orthopaedics, Midwest Center for Joint Replacement, Indianapolis, IN 46241, United States
Author contributions: Jones K, Musgrave M, and Penrose CT designed the research study; Jones K and Muehlmann AM performed the research and wrote the manuscript; Jones K, Muehlmann AM, Musgrave M, and Penrose CT edited the manuscript; All authors have read and approve the final manuscript.
Institutional review board statement: This study is exempt from Institutional Review Board approval as outlined in the US Code of Federal Regulations, 45 CFR 46.102.
Conflict-of-interest statement: Both Kirstin Jones and Amber M Muehlmann are paid employees of Exactech. Dr. Musgrave has no conflicts of interest to declare. Dr. Penrose is a paid consultant for Exactech.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Data sharing statement: No additional data are available from the authors for data sharing.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Amber M Muehlmann, PhD, Clinical Affairs, Exactech, Inc., 2320 NW 66th Court, Gainesville, FL 32653, United States. amber.muehlmann@exac.com
Received: February 21, 2025 Revised: April 28, 2025 Accepted: May 27, 2025 Published online: July 18, 2025 Processing time: 146 Days and 10.6 Hours
Abstract
BACKGROUND
Truliant® posterior stabilized (PS) and Truliant cruciate retaining (CR) are two designs used for total knee arthroplasty. Survivorship and reason for revision rates are now available from the American Joint Replacement Registry (AJRR) at short-term time points for both Truliant designs. It was hypothesized that Truliant PS and Truliant CR perform comparably to similar designs in terms of survivorship.
AIM
To analyze short-term survivorship of Truliant PS or CR total knee arthroplasty relative to non-Truliant PS or CR total knee arthroplasty.
METHODS
Utilizing data from the AJRR, a retrospective review was performed for subjects who underwent implantation of Truliant PS, Truliant CR, non-Truliant PS, and non-Truliant CR designs as of June 30, 2022. Survivorship and reasons for revision were compared statistically between Truliant PS vs non-Truliant PS as well as Truliant CR vs non-Truliant CR groups. Cumulative percent revision rates were compared across three registries, AJRR, Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), and the United Kingdom National Joint Registry (UK NJR).
RESULTS
Truliant PS survivorship was 97.95% at the four-year mark, while Truliant CR survivorship was 99.61% at the three-year mark. There were no significant differences in survivorship hazard ratios or reasons for revision for both Truliant groups vs non-Truliant comparison aggregate groups at short-term time points. Cumulative percent revision rate comparisons were made to device appropriate groups from AJRR, AOANJRR, and UK NJR data. Truliant PS cumulative percent revision rates were similar to non-Truliant cumulative percent revision rates in the AJRR and similar to AOANJRR and UKNJR at both one and three years. Truliant CR cumulative percent revision rates were lower than aggregate AJRR, AOANJRR, and UK NJR cumulative percent revision rates at the one-year and three-year marks.
CONCLUSION
This study demonstrates high survivorship for Truliant PS total knee arthroplasty out to four-years and Truliant CR total knee arthroplasty out to three-years of follow-up.
Core Tip: Short-term data on the Truliant Total Knee System in the posterior stabilized design show it performs at least as well as the aggregate of all other posterior stabilized total knee arthroplasties performed and recorded in the American Joint Replacement Registry and Australian Orthopaedic Association National Joint Replacement Registry databases. For the Truliant cruciate retaining design, short-term data show it performs better than the aggregate of all other cruciate retaining total knee arthroplasties performed and recorded in the American Joint Replacement Registry, the Australian Orthopaedic Association National Joint Replacement Registry, and the United Kingdom's National Joint Registry databases.
